# Teen Cannabinoid Hyperemesis Complicated by Wernicke Encephalopathy > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-teen-cannabinoid-hyperemesis-compli-2026-10-04/ > **Published:** 2026-10-04T22:30:10-04:00 | **Last Modified / Clinically Audited:** 2026-10-04T22:30:10-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Wernicke Encephalopathy Secondary to Cannabinoid Hyperemesis Syndrome in a 15-Year-Old Male Patient: A Case Re... --- CED Clinical Relevance #88 Verified [Clinical Evidence](https://cedclinic.com/hemp-gummies-pain-management-best-natural-remedies-2024/) Primary literature analysis of Wernicke Encephalopathy Secondary to Cannabinoid Hyperemesis Syndrome in a 15-Year-Old Male Patient: A Case Report.. Clinical Insight | CED Clinic This case report matters because it links a familiar cannabis-related emergency, recurrent cannabinoid hyperemesis syndrome, with a preventable neurologic complication that clinicians may not expect in adolescents. The patient had prolonged vomiting, 25 to 30 pounds of weight loss, confusion, ataxia, nystagmus, and confirmed thiamine deficiency. MRI and EEG were unremarkable, which is clinically important because normal testing can falsely reassure teams. In adolescents with suspected CHS, nutritional depletion should be treated as an active medical risk, not a secondary concern. Empiric thiamine is low risk, time-sensitive, and potentially vision-saving and brain-saving when neurologic signs emerge. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Teen Cannabinoid Hyperemesis Complicated by Wernic. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42781598/) Table of Contents - [Teen Cannabinoid Hyperemesis Complicated by Wernicke Encephalopathy](#Teen_Cannabinoid_Hyperemesis_Complicated_by_Wernicke_Encephalopathy)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Teen Cannabinoid Hyperemesis Complicated by Wernicke Encephalopathy A 15-year-old with chronic cannabis use developed thiamine-deficiency Wernicke encephalopathy after prolonged vomiting from cannabinoid hyperemesis syndrome, improving rapidly after empiric thiamine despite normal brain imaging. What This Study Teaches Us This case report describes one 15-year-old male with chronic cannabis use, presumed CHS, several weeks of intractable vomiting, 25 to 30 pounds of weight loss, hyponatremia, transaminitis, confusion, ataxia, nystagmus, confirmed thiamine deficiency, normal MRI and EEG, and neurologic improvement within one day of thiamine. There were no risk ratios or comparative endpoints because the evidence is a single-patient report. Why This Matters For patient care, the report reinforces that prolonged CHS can become a nutritional and neurologic emergency, not merely a recurrent vomiting diagnosis. It supports low-threshold empiric thiamine in adolescents with persistent vomiting, weight loss, and new neurologic findings, even when MRI is normal. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceCureusPublication Date2026AugEvidence LevelCase Reports, Journal ArticleFocus AreaTeen Cannabinoid Hyperemesis Complicated by Wernicke EncephaLead AuthorsJustin Abes, Melissa Bou Jaoude, Trinity Landrum, Janelle McGillDOI10.7759/cureus.115093PMIDPMID: 42781598 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Headline vs. Reality Truth Meter: Cannabis vomiting syndrome can cause brain damage in teens. **Primary Journal Data:** The primary evidence is a single pediatric case report: one 15-year-old male with chronic cannabis use, presumed CHS, prolonged vomiting, 25 to 30 pounds of weight loss, neurologic findings, confirmed thiamine deficiency, normal MRI and EEG, and rapid improvement after thiamine. **Dr. Caplan’s Clinical Verdict:** The report does not prove that cannabis directly causes Wernicke encephalopathy, but it strongly supports a practical warning: prolonged CHS can create severe nutritional depletion, and neurologic symptoms should trigger immediate thiamine treatment. Primary Analysis | Wernicke Encephalopathy Secondary to Can **Study Overview:** The use of cannabis and high-potency tetrahydrocannabinol (THC) products has risen substantially among adolescents, and cannabinoid hyperemesis syndrome (CHS) is now an increasingly recognized complication of chronic use. CHS is characterized by recurrent episodes of intractable nausea, vomiting, and abdominal pain that resolve with cannabis cessation. Wernicke encephalopathy (WE), a neurologic syndrome caused by thiamine deficiency, is classically associated with chronic alcohol use but is increasingly reported in nonalcoholic and pediatric patients, in whom atypical presentations complicate timely diagnosis. We report the case of a 15-year-old male patient with no significant past medical history and chronic cannabis use who developed WE in the setting of CHS. He initially presented with several days of intractable nausea, vomiting, and headache and was diagnosed with CHS. Symptoms persisted, and he returned weeks later with a 25- to 30-pound weight loss along with headache and dizziness. Repeat laboratory studies revealed worsening transaminitis and progressive hyponatremia, which was treated with fluid restriction and oral sodium supplementation. He was admitted for management of presumed CHS, and on admission demonstrated slowed speech, mild confusion, and episodes of unresponsiveness. Nephrology and gastroenterology were consulted. Several days into admission, he showed little cognitive improvement, remained bedbound, and developed an ataxic gait once movement was initiated. This was followed by new-onset horizontal nystagmus with blurred vision. Brain magnetic resonance imaging and electroencephalography were unremarkable, and a workup for encephalopathy was unrevealing. Given the constellation of nystagmus, ataxia, altered mentation, and protracted vomiting with significant weight loss, WE was suspected; a vitamin panel was ordered, and empiric thiamine was initiated. The vitamin panel subsequently confirmed thiamine deficiency. Within one day of thiamine supplementation, the patient’s nystagmus, gait, and cognitive function improved, consistent with a clinical diagnosis of WE likely secondary to CHS-induced thiamine deficiency. At follow-up, he reported cessation of cannabis, demonstrated adequate weight gain, and full neurologic recovery. To our knowledge, this is among the few reported cases of WE associated with CHS and highlights that normal MRI findings do not exclude the diagnosis. As adolescent THC use continues to rise, clinicians should maintain a low threshold for empiric thiamine supplementation in adolescents with prolonged CHS and any new neurologic findings, regardless of imaging results. **Primary Source & Scope:** Published in *Cureus* (2026Aug) conducted by Justin Abes, Melissa Bou Jaoude, Trinity Landrum, Janelle McGill. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42781598/) | **Primary Record:** DOI: 10.7759/cureus.115093 | PMID: 42781598 How Strong Is This Evidence? The evidence strength is appropriate for a sentinel clinical observation: a detailed case report with temporal sequence, neurologic phenotype, laboratory confirmation of thiamine deficiency, and rapid response to treatment. It is not statistically powered and provides no incidence estimate, dose-response curve, or comparative risk calculation. Where This Paper Deserves Skepticism The report cannot prove causality between cannabis exposure and Wernicke encephalopathy, because the proposed pathway depends on CHS-driven vomiting and nutritional depletion. Cannabis potency, exact exposure pattern, baseline diet, other substance use, gastrointestinal contributors, and all potential confounders may not be fully measurable in a case report. What This Paper Does Not Show This study does not show that all cannabis use causes thiamine deficiency or neurologic injury. It also does not establish a regulatory threshold for THC potency, adolescent exposure duration, or product type that predicts CHS or Wernicke encephalopathy. How This Fits With the Broader Clinical Conversation Clinical research into Wernicke Encephalopathy Secondary to Cannabinoid H is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, Wernicke Encephalopathy Secondary to Cannabinoid Hyperemesis Syndrome in a 15-Year-Old Male Patient: A Case Report. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away A teen with suspected CHS who develops confusion, abnormal eye movements, ataxia, or major weight loss should be treated as medically high risk. Cannabis cessation and empiric thiamine can be urgent, practical harm-reduction steps. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🌱GI and Gut](https://cedclinic.com/ask)[🧸Children and Teens](https://cedclinic.com/ask)[⚡GLP-1 and ECS](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Wernicke Encephalopathy Secondary to Cannabin requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Read this as a sentinel case report, not as a population estimate of how often CHS causes Wernicke encephalopathy. **Focus on the clinical sequence**prolonged vomiting and weight loss preceded neurologic decline, confirmed thiamine deficiency, and rapid improvement after replacement. **Critical Rule**Do not let normal MRI or EEG override classic bedside findings when thiamine deficiency is plausible and treatment delay may cause harm. Key Evaluation Question Does the clinical timeline make thiamine deficiency secondary to prolonged CHS more plausible than alternative causes of encephalopathy? The Patient Question Given prolonged vomiting and cannabis use, should thiamine, nutrition labs, electrolyte monitoring, and a neurologic exam be part of the treatment plan? The Bottom Line This single case report does not quantify risk, but it strongly supports early thiamine treatment when adolescents with CHS develop neurologic symptoms or substantial weight loss. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis This publication is a case report, not a cohort study or trial. Its evidentiary value comes from clinical sequence: chronic cannabis use, repeated vomiting, major weight loss, neurologic decline, confirmed thiamine deficiency, and rapid improvement after thiamine replacement. The negative MRI and EEG are central to the lesson. Wernicke encephalopathy can be a clinical diagnosis, especially when the classic triad of altered mentation, ataxia, and eye movement abnormalities appears after prolonged malnutrition or vomiting. Rigorous critical appraisal of study design, cohort size, and statistical controls ensures that clinical recommendations reflect verified therapeutic endpoints rather than speculative associations. Lens takeawayA single case cannot estimate incidence, but it can sharpen bedside vigilance. #### Patient Communication For families, the message should be direct without alarmism. Persistent vomiting in a teen who uses cannabis is not simply a stomach problem, and repeated dehydration or weight loss can deplete essential vitamins needed for brain function. Patients may minimize cannabis exposure unless asked in a nonjudgmental way. A useful conversation links cannabis cessation, nutrition, hydration, and urgent evaluation for confusion, dizziness, unsteady gait, vision changes, or abnormal eye movements. Open and transparent discussions with healthcare providers help clarify realistic treatment timelines, administration methods, and appropriate product selection. Lens takeawayClear cannabis history and neurologic symptom screening can prevent delayed treatment. #### Dosing & Formulations This report does not provide a safe THC dose, product threshold, or cannabinoid ratio that predicts CHS. The risk signal is chronic exposure, especially high-potency THC use in adolescents, combined with recurrent nausea and vomiting. From a clinical dosing perspective, the actionable intervention was not cannabis titration but thiamine replacement and cannabis cessation. Patients with established CHS generally require stopping THC exposure rather than switching products or adjusting dose. Individualized dose titration, documented cannabinoid ratios, and monitored therapeutic responses remain essential for maximizing clinical benefit while minimizing adverse side effects. Lens takeawayCHS management is cessation-centered, not a matter of finding a better THC ratio. #### Safety & Side Effect Profile The safety issue highlighted here is secondary harm. Cannabis did not need to directly injure the brain to create danger. Recurrent vomiting, caloric deficit, and vitamin depletion created the conditions for Wernicke encephalopathy. Thiamine treatment is typically low risk and should not be delayed when suspicion is high. In vomiting patients with confusion, ataxia, or nystagmus, waiting for vitamin levels or imaging confirmation may expose the brain to avoidable injury. Ongoing post-market surveillance, contaminant screening, and standardized adverse-event reporting remain critical safeguards for patient health. Lens takeawayProlonged vomiting plus neurologic findings should trigger urgent empiric thiamine. #### Regulatory & Policy Dynamics The case sits inside a broader adolescent exposure problem. High-potency THC products have become more accessible through legal and informal markets, while teen users may perceive cannabis as benign or medically harmless. Policy responses should avoid exaggeration but improve labeling, youth prevention, product potency education, and clinical screening. Emergency departments and pediatric practices also need protocols that recognize CHS and nutritional complications early. Consistent administrative oversight and clear statutory definitions ensure that public health protections keep pace with evolving consumer formulations. Lens takeawayRegulation should pair access rules with honest education about high-potency THC risks. #### Mechanisms & Physiology Wernicke encephalopathy reflects thiamine deficiency impairing cerebral energy metabolism, especially in vulnerable brain regions. Vomiting, reduced intake, weight loss, and metabolic stress can rapidly deplete thiamine stores, even without alcohol use. CHS likely involves dysregulation of cannabinoid signaling across gut, autonomic, and central pathways. In this case, the key pathophysiologic bridge was not intoxication but sustained emesis leading to nutritional failure and neurologic dysfunction. Investigating receptor affinities, pharmacokinetic pathways, and cellular interactions clarifies the biological mechanisms underlying observed clinical outcomes. Lens takeawayThe biologic link is nutritional depletion from CHS, not proven direct THC neurotoxicity. #### Research Limitations A one-patient case report cannot determine frequency, causality, dose response, or which adolescents with CHS are most vulnerable. Cannabis exposure details, potency, duration, route, and coexisting dietary factors may be incomplete. The diagnosis is clinically persuasive because symptoms improved after thiamine and deficiency was confirmed. Still, spontaneous improvement, concurrent supportive care, and unmeasured contributors cannot be fully separated in this design. Readers should carefully evaluate cohort composition, potential confounding variables, and study duration before generalizing preliminary findings across broader clinical populations. Lens takeawayThe report is a warning signal, not a population-level risk estimate. #### Future Outlook Future research should track adolescents presenting with CHS for weight loss, micronutrient deficiencies, neurologic signs, and outcomes after standardized thiamine protocols. Prospective registries would help identify who needs routine supplementation. Clinical systems can act before those data mature. Simple emergency department pathways could combine cannabis screening, vomiting duration, nutrition assessment, neurologic examination, thiamine replacement criteria, and clear counseling on cannabis cessation. Future prospective investigations with standardized formulations and long-term follow-up will provide critical clarity as clinical evidence matures. Lens takeawayBetter registries and protocols can convert rare case lessons into safer care. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Teen+Cannabinoid+Hyperemesis+Complicated+by+Wernicke+Encephalopathy&url=https%3A%2F%2Fcedclinic.com%2Fced-teen-cannabinoid-hyperemesis-compli-2026-10-04%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-teen-cannabinoid-hyperemesis-compli-2026-10-04%2F) [BlueSky](https://bsky.app/intent/compose?text=Teen+Cannabinoid+Hyperemesis+Complicated+by+Wernicke+Encephalopathy%20https%3A%2F%2Fcedclinic.com%2Fced-teen-cannabinoid-hyperemesis-compli-2026-10-04%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Wernicke Encephalopathy Secondary to Cannabinoid Hyperemesis Syndrome in a 15-Year-Old Male Patient: A Case Report.](https://pubmed.ncbi.nlm.nih.gov/42781598/) Related Reading at CED ClinicContinue exploring the evidence[Cannabinoids for Low Back Pain and Migraine: What Randomized Trials Actually Show](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/) More on this topic: Rigorous physician appraisal of randomized trials investigating cannabinoid efficacy for [chronic pain](https://cedclinic.com/cbd-gummies-chronic-pain/) and migraines. [More on this topic: Chronic pain & migraine](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[NY Times Response: Teens and Strong Cannabis](https://cedclinic.com/high-potency-cannabis-risks/) More on this topic: Critical discussion of high-potency THC products, youth exposure risks, and clinical communication with teens. [More on this topic: Youth & potency risks](https://cedclinic.com/high-potency-cannabis-risks/) ## Frequently Asked Questions What is cannabinoid hyperemesis syndrome? Cannabinoid hyperemesis syndrome, or CHS, is a pattern of recurrent severe nausea, vomiting, and abdominal pain associated with chronic cannabis use. Symptoms typically improve only after sustained cannabis cessation. What is Wernicke encephalopathy? Wernicke encephalopathy is a neurologic emergency caused by thiamine, vitamin B1, deficiency. Classic findings include confusion, abnormal eye movements, and ataxia, although not every patient shows all three signs at first. Did this case prove that cannabis directly caused brain injury? No. The report supports an indirect pathway: chronic cannabis use was associated with CHS, prolonged vomiting caused nutritional depletion, and thiamine deficiency led to Wernicke encephalopathy. Why can a normal MRI miss Wernicke encephalopathy? MRI can support the diagnosis, but it is not sensitive enough to exclude it. If the history and neurologic findings fit, clinicians should treat empirically rather than wait for imaging confirmation. Why is thiamine important in prolonged vomiting? Thiamine is required for brain energy metabolism. Vomiting, poor intake, and rapid weight loss can deplete thiamine stores and put the brain at risk for potentially reversible but serious injury. Should every adolescent with vomiting receive thiamine? Not necessarily every adolescent, but the threshold should be low when vomiting is prolonged, weight loss is significant, nutrition is poor, or neurologic symptoms such as confusion, nystagmus, dizziness, or unsteady gait appear. Can switching cannabis products prevent CHS? There is no reliable evidence that changing strains, routes, or THC to CBD ratios prevents CHS once the syndrome is established. Sustained cannabis cessation remains the most important intervention. What warning signs should families watch for? Urgent evaluation is warranted for persistent vomiting, dehydration, major weight loss, confusion, slowed speech, fainting or unresponsiveness, blurred vision, abnormal eye movements, dizziness, or trouble walking. How quickly can patients improve after thiamine? Some symptoms can improve rapidly when thiamine deficiency is treated early. In this case, nystagmus, gait, and cognitive function improved within one day of supplementation. What follow-up matters after CHS-related Wernicke encephalopathy? Follow-up should confirm cannabis cessation, nutritional recovery, weight restoration, neurologic resolution, and support for adolescent substance use counseling. Recurrence risk remains if cannabis use resumes. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).